<DOC>
	<DOCNO>NCT00068042</DOCNO>
	<brief_summary>The purpose study determine Pegvisomant efficacious Sandostatin LAR Depot normalize IGF-I level treatment naive patient acromegaly .</brief_summary>
	<brief_title>A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Diagnosis acromegaly IGFI level &gt; =1.3xULN ( upper limit normal ) screen No history radiotherapy prior treatment drug acromegaly Minimum two month must elapse post surgery prior screen Presence condition may result abnormal GH ( Growth Hormone ) and/or IGFI concentration AST/ALT &gt; = 3xULN ( upper limit normal ) Pituitary adenoma within 3mm optic chiasm confirm recent MRI Visual field defect ( except post surgical stable residual defect ) Unable self administer drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>